---
title: The Effect of a Charcoal Deactivation Pouch on Opioid Disposal After Cesarean Delivery
nct_id: NCT05498025
overall_status: COMPLETED
phase: NA
sponsor: Geisinger Clinic
study_type: INTERVENTIONAL
primary_condition: Pain, Acute
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05498025.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05498025"
ct_last_update_post_date: 2024-01-19
last_seen_at: "2026-05-12T06:48:38.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of a Charcoal Deactivation Pouch on Opioid Disposal After Cesarean Delivery

**NCT ID:** [NCT05498025](https://clinicaltrials.gov/study/NCT05498025)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 37
- **Lead Sponsor:** Geisinger Clinic
- **Conditions:** Pain, Acute, Opioid Misuse, Obstetric Pain, Cesarean Section Complications
- **Start Date:** 2023-02-21
- **Completion Date:** 2023-07-29
- **CT.gov Last Update:** 2024-01-19

## Brief Summary

Background: There is scarce literature investigating how patients dispose of unused opioid supplies after their cesarean postoperative pain has faded. The Office of the Surgeon General has identified research on the prevention of opioid use disorder area as well as research on the management of pain as a "Surgeon General Priority" that needs urgent investigation.

Hypothesis: At least 33% of postpartum women discharged home with an opioid prescription and a drug deactivation pouch will use the pouch to dispose of remaining opioids within 30 days of delivery.

Methods: This is a prospective single arm interventional pilot study.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 55 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion criteria:

* Age 18+ at time of enrollment, per ERM
* Delivered ≥26.0 weeks, per ERM
* Status post low transverse cesarean delivery, per ERM
* Physically located on labor \& delivery and is postpartum day #1 or #2 at time of enrollment, per ERM
* Opioid prescription has been sent (per ERM) or will be sent (per obstetric team).

Exclusion criteria:

* Positive urine toxicology anytime in pregnancy for non-prescription opioids, fentanyl, amphetamines, benzodiazepines, cannabinoids, LSD, or cocaine, per ERM.
* Buprenorphine or methadone Rx, per ERM
* Patient preferred communication language not English, per ERM
* Documented history, per ERM:

  * Cannabinoid use disorder
  * Hypnotic use disorder
  * Opioid use disorder
  * Stimulant use disorder
  * Fibromyalgia
  * Sickle cell anemia
  * Lumbar disc herniation
  * Multiple sclerosis
  * Trigeminal neuralgia
  * Active cancer
  * Complex regional pain syndrome
  * Systemic lupus erythematosus
  * Rheumatoid arthritis
```

## Arms

- **Activated charcoal pouch** (EXPERIMENTAL) — The patients in this arm will receive an activated charcoal pouch (Deterra Medium Pouch, UPC #: 850006727001, Verde Environmental Technologies, Minnetonka, MN) for disposal of their opioids after their cesarean delivery pain has resolved.

## Interventions

- **Deterra activated charcoal pouch** (OTHER) — drug disposal pouch

## Primary Outcomes

- **Actual pouch use** _(time frame: 30 days)_ — The percentage of women who used the pouch to dispose of opioids in the home 30 days after delivery (%)

## Locations (1)

- Geisinger Medical Center, Danville, Pennsylvania, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.geisinger medical center|danville|pennsylvania|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05498025.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05498025*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*